Introduction: glucagon beyond glycaemic counter-regulation

Glucagon has traditionally been framed as a single-purpose emergency hormone — the body's rapid-response system for hypoglycaemia. That view undersells its biology considerably. The glucagon receptor (GcgR) is broadly expressed across liver, adipose tissue, kidney, heart, and hypothalamus; its activation drives a constellation of hepatic metabolic effects — fatty-acid oxidation, thermogenic signalling, and ureagenesis — that are entirely distinct from its glucose-mobilising role. In the context of multi-receptor incretin pharmacology, controlled GcgR co-agonism provides the third pillar of effect that pushes triple-agonist compounds beyond the weight-loss ceiling observed with dual GIP/GLP-1 agents.

Endogenous glucagon physiology

Glucagon is a 29-amino-acid peptide produced by pancreatic α-cells. Secretion is stimulated by hypoglycaemia, amino-acid ingestion (particularly arginine), and the sympathetic nervous system during exercise or stress. Post-prandially, GLP-1 and GIP co-suppress glucagon release from α-cells, blunting hepatic glucose output at the appropriate time. Native glucagon has a plasma half-life of approximately 4–6 minutes, cleared by hepatic, renal, and plasma degradation. Its dominant target tissue is the liver, where portal glucagon concentrations are substantially higher than systemic levels, creating a liver-selective pharmacological gradient that therapeutic GcgR agonists aim to recapitulate.

GcgR pharmacology: receptor structure and signalling cascade

GcgR is a Class B GPCR sharing ~45% sequence homology with GLP-1R and ~47% with GIPR — reflecting the evolutionary divergence of the proglucagon gene product family. Agonist binding couples GcgR primarily to Gαs, raising intracellular cAMP and activating PKA. In hepatocytes, PKA phosphorylates and inactivates phosphofructokinase-2 (slowing glycolysis), activates phosphorylase kinase (accelerating glycogenolysis), and upregulates transcription of gluconeogenic enzymes (PEPCK, G6Pase) through CREB phosphorylation.

Beyond glucose metabolism, GcgR-mediated cAMP signalling in hepatocytes directly upregulates genes involved in mitochondrial fatty-acid β-oxidation (CPT1A, ACSL1, HADHA), promotes ketogenesis under fasting-like conditions, and stimulates ureagenesis — the conversion of amino-acid-derived nitrogen to urea, which is an ATP-demanding process contributing measurably to energy expenditure.

Hepatic energy expenditure: the metabolic-rate mechanism

The liver is responsible for approximately 20% of resting metabolic rate in humans, despite representing only ~2% of body mass, owing to its high metabolic activity. GcgR activation amplifies this contribution through several mechanisms:

Fatty-acid β-oxidation: GcgR-driven CPT1A upregulation increases mitochondrial import of long-chain fatty acyl-CoAs, accelerating oxidation and ATP/heat production. This simultaneously reduces hepatic triglyceride accumulation — a direct benefit in MASLD.
Futile cycling and uncoupling: In both liver and brown adipose tissue, glucagon receptor activation upregulates uncoupling protein 1 (UCP1) expression, dissipating the proton gradient across the inner mitochondrial membrane as heat rather than ATP synthesis — a thermogenic mechanism that increases calorie expenditure without requiring mechanical work.
Ureagenesis: The ornithine cycle requires five ATP equivalents per molecule of urea produced. GcgR-driven ureagenesis is quantitatively meaningful; fasting glucagon surges are associated with measurable increases in urea nitrogen excretion and estimated hepatic oxygen consumption.

Together these mechanisms create a sustained elevation in resting metabolic rate that is additive to the caloric deficit generated by reduced appetite via GLP-1R signalling. In mechanistic modelling of retatrutide's weight-loss trajectory, the GcgR-mediated metabolic-rate component is estimated to account for a meaningful fraction of the incremental weight loss over dual agonism alone.

The hyperglycaemia paradox — and why co-agonism resolves it

The most significant obstacle to developing GcgR agonists as stand-alone therapeutics is their intrinsic tendency to raise blood glucose via hepatic glycogenolysis and gluconeogenesis. Isolated GcgR activation cannot safely be titrated to doses that produce meaningful metabolic-rate elevation without provoking unacceptable hyperglycaemia.

The intellectual breakthrough underlying triple-agonist design was recognising that GLP-1R and GIPR co-agonism can fully counterbalance GcgR-driven glucose output. When GLP-1R-mediated glucose-dependent insulin secretion is active, hepatic glycogenolysis is suppressed at the post-receptor level and peripheral glucose disposal is enhanced — exactly offsetting GcgR-driven glucose mobilisation. Phase 1/2 data for retatrutide demonstrate that despite containing a meaningful GcgR agonist moiety, the compound produces no net hyperglycaemia and delivers glycaemic improvement comparable to semaglutide — the metabolic-rate upside without the glucose cost.

Retatrutide: the clinical proof of concept

Retatrutide (Eli Lilly, LY3437943) is a single synthetic peptide with balanced agonism at GIP, GLP-1, and glucagon receptors. In the Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide at 12 mg once weekly produced mean body weight reductions of 17.5% at 24 weeks and approximately 24% in participants completing 48 weeks of treatment — figures that exceed tirzepatide's Phase 2 trajectory and approach the weight loss achieved by bariatric surgery in some analyses.

Mechanistically, the Phase 2 data are consistent with GcgR contributing a sustained energy-expenditure component: the weight-loss curve with retatrutide does not plateau at the same point as dual agonists, suggesting ongoing metabolic-rate elevation preventing the adaptive thermogenesis-driven plateau that typically attenuates GLP-1R-only weight loss. ALT normalisation and hepatic fat fraction reductions in the trial are also consistent with the hepatic fatty-acid oxidation mechanism described above.

Beyond weight: MASLD and cardiovascular implications

Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD/NASH) is an area where GcgR co-agonism may provide differentiated clinical benefit. Standalone GLP-1 receptor agonists reduce hepatic fat to a degree; GcgR agonism adds direct stimulation of hepatic lipid export and oxidation that is mechanistically complementary rather than redundant. Early MASLD data for retatrutide and investigational GLP-1/GcgR dual agonists suggest liver fat reduction approaching 50–70% from baseline — substantially exceeding GLP-1R monotherapy benchmarks.

Cardiovascular modelling is early-stage, but GcgR expression in cardiomyocytes and the positive inotropic effect of glucagon (historically used in beta-blocker overdose management) raises the hypothesis that controlled GcgR agonism may have direct cardioprotective effects layered atop GLP-1R-mediated cardiovascular benefit — a question that CVOT design for triple agonists will need to address.

Why this matters for next-generation compound design

The triple-agonist paradigm established by retatrutide has opened a design space for peptides that intentionally uncouple caloric restriction (driven by GLP-1R/GIPR appetite suppression) from energy expenditure (driven by GcgR metabolic activation). Achieving body weight reductions of 25–30% pharmacologically — approaching the effect magnitude of sleeve gastrectomy — may require this two-pronged strategy. Programmes extending beyond triple agonism, incorporating FGF21 receptor co-agonism or GIP/GLP-1/ GcgR/amylin quadruple targeting, are now in pre-clinical development and will depend entirely on the mechanistic groundwork established by GcgR pharmacology.

Glucagon receptor pharmacology